GTS Securities LLC Grows Stock Holdings in Abbott Laboratories (NYSE:ABT)

GTS Securities LLC boosted its holdings in shares of Abbott Laboratories (NYSE:ABT - Free Report) by 164.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 11,776 shares of the healthcare product maker's stock after purchasing an additional 7,318 shares during the quarter. GTS Securities LLC's holdings in Abbott Laboratories were worth $1,332,000 as of its most recent SEC filing.

Several other institutional investors have also bought and sold shares of ABT. Redwood Park Advisors LLC purchased a new stake in Abbott Laboratories during the 4th quarter valued at $25,000. Noble Wealth Management PBC bought a new position in Abbott Laboratories during the fourth quarter valued at $26,000. NewSquare Capital LLC raised its stake in shares of Abbott Laboratories by 78.4% in the fourth quarter. NewSquare Capital LLC now owns 239 shares of the healthcare product maker's stock valued at $27,000 after acquiring an additional 105 shares during the period. WealthTrak Capital Management LLC bought a new stake in shares of Abbott Laboratories in the 4th quarter worth about $28,000. Finally, Rialto Wealth Management LLC purchased a new position in shares of Abbott Laboratories during the 4th quarter worth about $29,000. Institutional investors own 75.18% of the company's stock.

Analyst Upgrades and Downgrades

Several analysts have issued reports on ABT shares. Royal Bank of Canada raised their price objective on shares of Abbott Laboratories from $140.00 to $145.00 and gave the stock an "outperform" rating in a research note on Thursday, April 17th. Morgan Stanley raised their price target on Abbott Laboratories from $117.00 to $127.00 and gave the stock an "equal weight" rating in a research note on Thursday, April 17th. Barclays boosted their price objective on Abbott Laboratories from $158.00 to $159.00 and gave the company an "overweight" rating in a report on Thursday, April 17th. Piper Sandler reiterated an "overweight" rating and issued a $145.00 target price (up previously from $133.00) on shares of Abbott Laboratories in a research note on Thursday, April 17th. Finally, Bank of America upped their price target on shares of Abbott Laboratories from $133.00 to $150.00 and gave the stock a "buy" rating in a report on Monday, March 10th. Four equities research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, Abbott Laboratories currently has a consensus rating of "Moderate Buy" and an average price target of $142.59.

Abbott Laboratories Stock Up 0.6%

NYSE ABT traded up $0.78 on Thursday, hitting $132.80. The stock had a trading volume of 3,073,058 shares, compared to its average volume of 6,123,653. Abbott Laboratories has a 52-week low of $99.71 and a 52-week high of $141.23. The business's fifty day moving average price is $130.19 and its 200 day moving average price is $124.95. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.60 and a quick ratio of 1.14. The stock has a market cap of $231.04 billion, a price-to-earnings ratio of 17.36, a price-to-earnings-growth ratio of 2.52 and a beta of 0.74.

Abbott Laboratories (NYSE:ABT - Get Free Report) last released its earnings results on Wednesday, April 16th. The healthcare product maker reported $1.09 EPS for the quarter, topping analysts' consensus estimates of $1.07 by $0.02. Abbott Laboratories had a net margin of 31.95% and a return on equity of 20.74%. The company had revenue of $10.36 billion during the quarter, compared to analysts' expectations of $10.38 billion. Equities research analysts anticipate that Abbott Laboratories will post 5.14 earnings per share for the current year.

Insider Activity at Abbott Laboratories

In other Abbott Laboratories news, SVP Eric Shroff sold 562 shares of the company's stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $138.17, for a total transaction of $77,651.54. Following the completion of the transaction, the senior vice president now directly owns 31,970 shares in the company, valued at approximately $4,417,294.90. This represents a 1.73% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Andrea F. Wainer sold 949 shares of the business's stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $138.17, for a total transaction of $131,123.33. Following the sale, the executive vice president now directly owns 74,381 shares of the company's stock, valued at $10,277,222.77. This represents a 1.26% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 95,278 shares of company stock valued at $12,745,859 in the last ninety days. Company insiders own 0.46% of the company's stock.

Abbott Laboratories Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.